Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer-Reference-Cited by-同舟云学术

Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer

Published:2013-08 Issue:8 Volume:9 Page:1083-1092
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Viola David¹,Cappagli Virginia¹,Elisei Rossella²

Affiliation:

1. Endocrinology Unit, Department of Clinical & Experimental Medicine, WHO Collaborating Center for the Study & Treatment of Thyroid Diseases & other Endocrine & Metabolic Disorders, University of Pisa, Via Paradisa 2, Pisa 56124, Italy

2. Endocrinology Unit, Department of Clinical & Experimental Medicine, WHO Collaborating Center for the Study & Treatment of Thyroid Diseases & other Endocrine & Metabolic Disorders, University of Pisa, Via Paradisa 2, Pisa 56124, Italy. .

Abstract

Cabozantinib (XL184) is an oral multiple receptor tyrosine kinase inhibitor manufactured by Exelixis Inc., CA, USA. It mainly inhibits three tyrosine kinase receptors: MET, VEGFR2 and RET. In both preclinical and clinical studies it has been shown to inhibit tumor angiogenesis, invasiveness and metastases. The most frequent side effects are fatigue, diarrhea, decreased appetite, nausea, weight loss and palmar–plantar erythrodysesthesia. A Phase III clinical trial (EXAM study) of XL184 versus placebo in advanced and progressive medullary thyroid cancer showed a 28 versus 0% overall response rate and a progression-free survival of 11.2 versus 4.0 months (hazard ratio: 0.28; 95% CI: 0.19–0.40; p < 0.0001) in patients treated with cabozantinib and placebo, respectively. The drug has been approved by the US FDA for the treatment of advanced/progressive metastatic medullary thyroid cancer in the USA. The EMA is now evaluating its approval in Europe.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon.13.128

Reference49 articles.

1. De LellisRA, Lloyd RV, Heitz PU, Eng C. WHO Classification of Tumours. In:Pathology and Genetics of Tumours of Endocrine Organs. DeLellis RA (Ed.). ARC Press, Lyon, France,49–133 (2004).

2. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002

3. Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association

4. Multiple endocrine neoplasia type 2

5. Medullary Thyroid Carcinoma: Clinicopathologic Features and Long-Term Follow-Up of 65 Patients Treated During 1946 Through 1970

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade;Frontiers in Endocrinology;2023-11-20

2. Hetero Cyclic Compounds in the Treatment of Triple-Negative Breast Cancer;Current Cancer Therapy Reviews;2023-08

3. Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors;Frontiers in Chemistry;2022-11-17

4. Stato nutrizionale e risposta al trattamento con inibitori tirosino-chinasici nel carcinoma tiroideo avanzato;L'Endocrinologo;2022-11-10

5. Prostate cancer immunotherapy;Expert Opinion on Biological Therapy;2022-01-16